<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="prominent antiviral effects in cells. They downregulated the expression of" exact="viral" post="proteins, including the VP40 matrix protein and the envelope"/>
 <result pre="in addition to VP24 (nucleocapsid-associated protein), VP30 (an activator of" exact="viral" post="transcription), VP35 (a type I interferon antagonist and a"/>
 <result pre="(nucleocapsid-associated protein), VP30 (an activator of viral transcription), VP35 (a" exact="type I" post="interferon antagonist and a polymerase cofactor) and RNA dependent"/>
 <result pre="polymerase (L), and non-structural proteins such as sGP (3-6). Efficient" exact="viral infection" post="requires at least two cellular receptors, the endo/lysosomal cholesterol"/>
 <result pre="(L), and non-structural proteins such as sGP (3-6). Efficient viral" exact="infection" post="requires at least two cellular receptors, the endo/lysosomal cholesterol"/>
 <result pre="T-cell immunoglobulin and mucin domain 1 (TIM-1) (7, 8). The" exact="viral" post="ribonucleocapsid (NC) consisting of the helical NP-viral RNA (vRNA)"/>
 <result pre="negative sense vRNA is transcribed into mRNA for synthesis of" exact="viral" post="proteins and complementary RNA for further vRNA amplification. During"/>
 <result pre="(10). Since 1976 when this virus was first identified, its" exact="infection" post="has caused Ebola hemorrhagic fever (EHF) in humans with"/>
 <result pre="fatality rates exceeding 50% (available online at https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease). The West" exact="African" post="EBOV epidemic from 2014 to 2016 was the worst"/>
 <result pre="is imperative to develop prophylactic or therapeutic antivirals against EBOV" exact="infection" post="(12). Several high-throughput screening (HTS) methods, including monocistronic minigenome"/>
 <result pre="high-throughput screening (HTS) methods, including monocistronic minigenome technology and pseudotyped" exact="viral" post="particle systems, have been developed to identify antiviral compounds"/>
 <result pre="research with live EBOV is restricted. However, these methods enable" exact="limited" post="targeting of the viral RNA transcription/replication or entry steps"/>
 <result pre="is restricted. However, these methods enable limited targeting of the" exact="viral" post="RNA transcription/replication or entry steps by the antiviral compounds."/>
 <result pre="identify antiviral compounds by targeting virtually every stage of the" exact="viral" post="life cycle (17). Here, the tetracistronic minigenomes carrying a"/>
 <result pre="Here, the tetracistronic minigenomes carrying a reporter gene and three" exact="viral" post="genes encoding structural proteins VP40, GP and VP24, flanked"/>
 <result pre="Co-transfection of this tetracistronic construct with five additional plasmids expressing" exact="viral" post="proteins for RNA synthesis, including NP, VP30, VP35 and"/>
 <result pre="and replication of the minigenome and leads to generation of" exact="infectious" post="progeny VLPs encapsulating the minigenome RNA. Eventually, trVLPs acquire"/>
 <result pre="to infect other target cells expressing TIM-1 and the four" exact="viral" post="proteins, NP, VP30, VP35 and L, for the second-round"/>
 <result pre="The majority of these compounds have been used to treat" exact="psychotic disorders" post="or allergic diseases by binding to G protein-coupled receptors"/>
 <result pre="levels of the three compounds exhibit anti-EBOV activity. Inhibition of" exact="viral" post="protein expression and generation of viral progeny To investigate"/>
 <result pre="anti-EBOV activity. Inhibition of viral protein expression and generation of" exact="viral" post="progeny To investigate whether the antiviral compounds reduce viral"/>
 <result pre="of viral progeny To investigate whether the antiviral compounds reduce" exact="viral" post="protein levels and generation of progeny trVLP, we performed"/>
 <result pre="as RBV, a positive control, whereas the amount of another" exact="viral" post="protein, NP, expressed via the plasmid-derived CAG promoter remained"/>
 <result pre="of cytoplasmic GP levels in the trVLP-infected cells (Fig. 3B)." exact="Total" post="fluorescent spots per well were quantified by collecting images"/>
 <result pre="2). We investigated whether their inhibition suppressed the production of" exact="infectious" post="trVLPs. Culture supernatants were harvested to quantify the relative"/>
 <result pre="that sertindole, raloxifene and ibutamoren not only prevent trVLP-derived EBOV" exact="viral" post="replication in cells but also subsequently block the generation"/>
 <result pre="such as dengue virus and rhinovirus (25-27). We found no" exact="viral" post="inhibition in cells, indicating that the hit compounds are"/>
 <result pre="as evaluation of its efficacy against wild-type, highly pathogenic Ebola" exact="viral" post="strains remains to be investigated. In the absence of"/>
 <result pre="pathogenic Ebola viral strains remains to be investigated. In the" exact="absence of" post="any clinically available antiviral drug, this study informs that"/>
 <result pre="Cells, plasmids and chemicals HEK293T cells were purchased from the" exact="American" post="Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified"/>
 <result pre="promoter and for the expression of T7 RNA polymerase (pCAGGS-T7)," exact="viral" post="proteins (pCAGGS-NP, -VP30, -VP35 and -L) and TIM-1 (pCAGGS-Tim1)"/>
 <result pre="harvested using the M-PER buffer (Thermo Scientific). Twenty micrograms of" exact="total" post="protein per well were loaded on the 10% or"/>
 <result pre="SDS-PAGE and electrophoretically transferred to a polyvinylidene fluoride membrane (Millipore)." exact="Viral" post="proteins were detected using primary antibodies specific for VP40"/>
 <result pre="a polyvinylidene fluoride membrane (Millipore). Viral proteins were detected using" exact="primary" post="antibodies specific for VP40 (Cat. no. 40446-T48; Sino Biological)"/>
 <result pre="Sino Biological), followed by a horseradish peroxidase (HRP)-conjugated goat anti-rabbit" exact="secondary" post="antibody (Thermo Scientific). The cellular β-actin protein, a loading"/>
 <result pre="β-actin protein, a loading control, was detected with an anti-β-actin-specific" exact="primary" post="antibody (Cat. No. A1987; Sigma) and the HRP-conjugated goat"/>
 <result pre="antibody (Cat. No. A1987; Sigma) and the HRP-conjugated goat anti-mouse" exact="secondary" post="antibody (Thermo Scientific). Confocal microscopy Plasmids expressing polymerase complex"/>
 <result pre="medium containing 4,6-diamidino-2-phenylindole (DAPI; Vector Laboratories). Confocal fluorescent images were" exact="acquired" post="using Zeiss LSM 700 (Carl Zeiss). The number of"/>
 <result pre="In brief, tetracistronic trVLP RNA was purified using a QIAamp" exact="Viral" post="RNA kit (Qiagen) on day 2 p.i. Following reverse-transcription,"/>
 <result pre="and buddingJ Virol81114521146010.1128/JVI.00853-0717699576 5BiedenkopfNSchlerethJGrunwellerABeckerSHartmannRK2016RNA Binding of Ebola Virus VP30 Is" exact="Essential" post="for Activating Viral TranscriptionJ Virol907481749610.1128/JVI.00271-1627279615 6BanadygaLHoenenTAmbroggioXDunhamEGrosethAEbiharaH2017Ebola virus VP24 interacts"/>
 <result pre="5BiedenkopfNSchlerethJGrunwellerABeckerSHartmannRK2016RNA Binding of Ebola Virus VP30 Is Essential for Activating" exact="Viral" post="TranscriptionJ Virol907481749610.1128/JVI.00271-1627279615 6BanadygaLHoenenTAmbroggioXDunhamEGrosethAEbiharaH2017Ebola virus VP24 interacts with NP to"/>
 <result pre="of approved drugsEmerg Microbes Infect3e8410.1038/emi.2014.8826038505 15WangYCuiRLiGet al.2016Teicoplanin inhibits Ebola pseudovirus" exact="infection" post="in cell cultureAntiviral Res1251710.1016/j.antiviral.2015.11.00326585243 16WelchSRGuerreroLWChakrabartiAKet al.2016Lassa and Ebola virus"/>
 <result pre="against human rhinovirusACS Med Chem Lett966767210.1021/acsmedchemlett.8b0013430034598 27JangYShinJSYoonYSet al.2018Salinomycin inhibits influenza" exact="virus infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="human rhinovirusACS Med Chem Lett966767210.1021/acsmedchemlett.8b0013430034598 27JangYShinJSYoonYSet al.2018Salinomycin inhibits influenza virus" exact="infection" post="by disrupting endosomal acidification and viral matrix protein 2"/>
 <result pre="al.2018Salinomycin inhibits influenza virus infection by disrupting endosomal acidification and" exact="viral" post="matrix protein 2 functionJ Virol92e014411810.1128/JVI.01441-1830282713 28SvenssonJLonnLJanssonJOet al.1998Two-month treatment of"/>
 <result pre="compounds (each at 10 μM). The green box highlights 86" exact="primary" post="hits that suppressed trVLP replication below 15% and maintained"/>
 <result pre="from two independent experiments in triplicate. Fig. 3 Inhibition of" exact="viral" post="protein expression and progeny trVLP generation. (A) Western blot"/>
 <result pre="NP (middle), or β-actin (lower). -V, no transfection and no" exact="infection" post="control. M, trVLP-infected, DMSO-treated mock control. (B) Confocal microscopy"/>
 <result pre="trVLP-infected, DMSO-treated mock control. (B) Confocal microscopy for detection of" exact="viral" post="GP. HEK293T cells were transfected and infected with trVLP"/>
 <result pre="1 p.i., cells were fixed and permeabilized to probe the" exact="viral" post="GP with an anti-GP antibody and an Alexa488-conjugated secondary"/>
 <result pre="the viral GP with an anti-GP antibody and an Alexa488-conjugated" exact="secondary" post="antibody (green). Nuclei were counterstained with DAPI (blue). Original"/>
 <result pre="Raloxifene 0.5 ± 0.0 25.6 ± 0.2 47.1 ± 2.2" exact="Selective" post="estrogen receptor modulator 11 Proadifen 2.7 ± 0.7 &amp;gt;"/>
</results>
